Skip to main content

Table 6 Distribution of mouth opening, tongue protrusion, cheek flexibility according to group in different time periods

From: Effectiveness of Pentoxifylline in the treatment of oral submucous fibrosis patients: a case-control study

CLINICAL EXAMINATION GroupNMeanStd. DeviationU valueP value
MOUTH OPENING (mm)BaselinePentoxyfylline4026.79067.85162  
Placebo4025.75007.931160.5270.600
1st MonthPentoxyfylline4027.85637.69147  
Placebo4026.71887.349500.6050.547
2nd MonthPentoxyfylline4028.44847.82333  
Placebo4026.93757.352580.7960.429
3rd MonthPentoxyfylline4029.13137.87435  
Placebo4026.96887.328621.1370.260
TONGUE PROTRUSIONBaselinePentoxyfylline4031.28138.48997  
Placebo4031.03139.626860.1100.913
1st MonthPentoxyfylline4033.12508.71317  
Placebo4032.62509.957170.2140.831
2nd MonthPentoxyfylline4034.37508.85274  
Placebo4033.781310.168690.2490.804
3rd MonthPentoxyfylline4034.75008.90451  
Placebo4034.125010.117850.2620.794
BaselinePentoxyfylline40.8856.18243  
CHEEK FLEXIBILITYPlacebo40.9348.225510.9580.342
1st MonthPentoxyfylline40.9135.18642  
Placebo40.9401.227070.5110.611
2nd MonthPentoxyfylline40.9144.19621  
Placebo40.9441.228400.5570.579
3rd MonthPentoxyfylline403.857516.63277  
Placebo40.9467.229380.9900.326